Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

by | Apr 23, 2026 | Clinical Trials | 0 comments

​ Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions: Drug: Tislelizumab Plus Chemotherapy

Sponsors: Shandong Provincial Hospital

Recruiting Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions: Drug: Tislelizumab Plus Chemotherapy
Sponsors: Shandong Provincial Hospital
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *